RVMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now for a rebound-style trade. RVMD is sitting just above first support (~96.2) after the Merck deal-clearing drop, while options positioning is strongly call-skewed and Street targets were broadly reset much higher into a catalyst-heavy 2026. Technically the trend is still bearish (negative MACD), but the stock is near a logical stabilization zone (96–100). With an impatient profile (not waiting for perfect entries), the current level offers a favorable near-term risk/reward for a bounce back toward ~108–121 if sentiment normalizes and attention shifts back to clinical milestones and/or renewed M&A interest.
Price/Trend: RVMD is trading at 98.3, below the pivot (108.396), indicating the stock is still in a post-gap-down recovery zone rather than a confirmed uptrend. Momentum: MACD histogram is -3.351 and negatively expanding, which signals bearish momentum is still present (downtrend pressure hasn’t fully faded yet). RSI: RSI_6 at 31.493 is near oversold territory, consistent with a selloff that may be close to exhaustion and prone to a bounce. Moving averages: Converging moving averages suggests the prior trend is losing clarity—often seen during transition periods after large event-driven moves. Levels: Immediate support S1 ~96.175 (price is just above it). If that breaks, S2 ~88.626 is the next downside magnet. Resistance levels to reclaim are the pivot ~108.396, then R1 ~120.616. Pattern-based forward look: Similar-pattern stats indicate ~50% chance of -2.58% next day and -3% next week, but +11.98% next month—consistent with near-term chop followed by rebound potential.
Intellectia Proprietary Trading Signals
Catalyst-rich 2026 setup: Multiple Street notes emphasize major upcoming milestones (not fully detailed in the dataset but repeatedly referenced as “catalyst rich”).
M&A remains a lingering theme: Despite Merck stepping away, multiple analysts frame this as a “clearing event” and still see strategic demand for novel oncology assets (some still view a deal as “more likely than not”).
Options sentiment is bullish (very low put/call ratios), supporting the idea of dip buyers stepping in.
Upcoming earnings date (QDEC 2025 earnings on 2026-02-26 after hours) can refocus investors on runway/operating discipline and pipeline progress rather than just M&A headlines.
Deal break headline overhang: News flow confirms Merck is no longer in acquisition talks, which triggered a sharp drop and can keep a cap on near-term multiple expansion.
Technical momentum still bearish: MACD is negative and expanding, so further downside tests (96 then ~88.
are possible before a clean uptrend resumes.
Pre-revenue biotech profile: With no revenue and ongoing losses, the stock remains highly sentiment-driven and dependent on pipeline execution and/or strategic interest.
Near-term trading could stay choppy: Similar-pattern stats suggest mild negative bias over the next day/week even if the 1-month outlook improves.
Latest quarter provided: 2025/Q3.
Trend: Ratings are broadly bullish (Buy/Outperform/Overweight) with a major upward reset in price targets in January 2026, driven largely by M&A speculation and increased visibility into the pipeline’s Phase 3 path. Recent notable changes:
